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Background: In a phase I clinical trial, a H5N1 pandemic live attenuated influenza virus
(pLAIV) VN2004 vaccine bearing avian influenza H5N1 hemagglutinin (HA) and NA genes
on the A/Ann Arbor cold-adapted vaccine backbone displayed very restricted replication.
We evaluated T cell responses to H5N1 pLAIV vaccination and assessed pre-existing
T cell responses to determine whether they were associated with restricted replication of
the H5N1 pLAIV.
Method: ELISPOT assays were performed using pools of overlapping peptides spanning
the entire H5N1 proteome and the HA proteins of relevant seasonal H1N1 and H3N2
viruses. We tested stored peripheral blood mononuclear cells (PBMCs) from 21 study
subjects who received two doses of the H5N1 pLAIV. The PBMCs were collected 1day
before and 7days after the first and second pLAIV vaccine doses, respectively.
Result: T cell responses to conserved internal proteins M and NP were significantly
boosted by vaccination (p=0.036). In addition, H5N1 pLAIV appeared to preferentially
stimulate and boost pre-existing seasonal influenza virus HA-specific T cell responses
that showed low cross-reactivity with the H5 HA. We confirmed this observation by T cell
cloning and identified a novel HA-specific epitope. However, we did not find any evidence
that pre-existing T cells prevented pLAIV replication and take.
Conclusion: We found that cross-reactive T cell responses could be boosted by
pLAIV regardless of the induction of antibody. The impact of the “original antigenic
sin” phenomenon in a subset of volunteers, with preferential expansion of seasonal
influenza-specific but not H5N1-specific T cell responses merits further investigation.
Keywords: influenza, H5N1, vaccine, T cells, LAIV, peptide, epitope, antigenic sin
Introduction
Influenza is a global public health problem, with seasonal epidemics caused by human H1N1,
H3N2, and B viruses, and sporadic disease caused by avian influenza A viruses, which can lead
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to severe illness in humans (1–4). Live attenuated influenza vac-
cines (LAIV) that contain the A/Ann Arbor cold-adapted (AA ca)
backbone (5) are immunogenic and protective and are licensed for
protection against seasonal influenza (6–8). We have generated
and evaluated candidate live attenuated vaccines for pandemic
use (pLAIVs) bearing avian influenza A hemagglutinin (HA)
and neuraminidase (NA) genes on the AA ca vaccine backbone.
The H5N1 pLAIV (VN2004) bearing the HA and NA genes
from the A/Vietnam/1203/2004 (H5N1) virus was evaluated in
a phase I clinical trial (NCT00347672) (9). The infectivity of
the H5N1 pLAIV was assessed by virus isolation and rRT-PCR
amplification of vaccine virus from daily nasal washes and the
immunogenicity of the vaccine was assessed by serologic methods
including hemagglutination inhibition (HAI) and microneutral-
ization and ELISA assays. The replication of the vaccine virus was
highly restricted and the vaccine failed to elicit robust antibody
responses (9).
Although antibody responses to inactivated influenza vaccine
correlate with protection, several lines of evidence show that post-
vaccination antibody titers are not the sole surrogate for vaccine
efficacy, especially for LAIV (10–13). Several studies demonstrate
that regardless of the presence of the antibody, influenza-specific
T cell responses correlate with viral clearance (14, 15). The “Cleve-
land Family study” showed that protection from influenza cor-
related with T cell responses, and cross-reactive T cell responses
might contribute to the protection (16). Therefore, as suggested by
Schotsaert et al., the correlation of vaccine efficacywith alternative
measures of immune function such as influenza-specific T cell
responses warrants further attention (17).
In this study, we evaluated the T cell responses in peripheral
blood mononuclear cells (PBMCs) from the cohort of study sub-
jects who received two doses of the H5N1 VN 2004 ca vaccine
approximately 50 days apart (9). T cell responses to overlapping
peptide pools spanning the entire H5N1 proteome, as well as
the HA proteins of relevant seasonal influenza viruses, were
evaluated before and 7 days after each vaccination. We found
that T cell responses with effector phenotypes were boosted
by vaccination, regardless of vaccine infectivity or the serum
HAI titer elicited. The potential role of pre-existing T cell




Nineteen healthy volunteers received two doses of the H5N1
VN 2004 pLAIV approximately 50 days apart, and two additional
volunteers received only one dose (9). Blood samples were taken
from each of the study subject at four time points: pre-vaccination,
7 days after the first dose of vaccine, 1 day prior to the second
dose of vaccine, and 7 days after the second dose of vaccine. The
study subjects were divided into two groups according to their
infection status. Infection with the vaccine virus was inferred if
the study subjects shed vaccine virus in culture, were RT-PCR
positive after day 1, and/or demonstrated a fourfold or greater rise
in serumantibody titer (9). Ethical approvalwas obtained from the
Committee onHuman Research Institutional Review Board (IRB)
of the Johns Hopkins Bloomberg School of Public Health and the
Institutional Biosafety Committee of Johns Hopkins University.
Informed consent was obtained from all participating individuals
prior to the study (9). The ClinicalTrials.gov identifier for this
study is NCT00347672.
In order to understand the priming of the immune system
induced by the H5N1 pLAIV, subjects who received two doses of
the H5N1 VN 2004 pLAIV were contacted 4 years after receipt of
the pLAIV and invited to participate in a follow-up study. Eleven
subjects returned for this additional booster dose of 45µg of
the H5N1 inactivated unadjuvanted subvirion influenza vaccine
(ISIV) (NCT01109329) (18). Antibody responses were measured
after the boost dose, and comparedwith subjects whohad received
a non-H5N1 pLAIV or the ISIV alone (18).
Synthetic Peptides for T Cell Analysis
A total of 890 15- to 18-mer peptides overlapping by 10 amino
acid residues and spanning the full avian influenza H5N1 pro-
teome and seasonal influenza H3N2/H1N1 HA proteins was syn-
thesized by Sigma-Aldrich (Haverhill, Suffolk, UK) and used in
our previous study (19). The peptides were dissolved in DMSO
(Sigma-Aldrich) at 40mg/ml anddilutedwithRPMI 1640 (Sigma-
Aldrich) to a concentration of 2mg/ml (long-term stock, stored
at  80°C) before being individually filtered and combined into
different pools: H1 HA, H3 HA, H5 HA, M, and NP (40–90
peptides/pool).
Ex Vivo IFNγ ELISPOT Assay
Cryopreserved PBMCs were thawed in a 37°C water bath
and re-suspended in RPMI 1640 supplemented with 2% v/v
heat-inactivated fetal calf serum (FCS, Sigma-Aldrich), 2mM -
glutamine (Sigma-Aldrich), 1% v/v (100U/ml) penicillin strepto-
mycin (Sigma-Aldrich) (R2 medium), and 60µg/ml DNase solu-
tion (Type IV, Sigma-Aldrich) for 15min at 37°C. Cells were
washed and re-suspended in R10 medium (RPMI1640, 10% FCS,
2mM -glutamine, and 1% PenStrep) and rested overnight at
a concentration of 106 cells/ml. PBMCs (200,000) with 2µg/ml
the concentration of a single peptide in the pool or 400 T
cells/clone with 20,000 peptide-pulsed Epstein–Barr virus trans-
formed B cells were used in standard human IFNγ ELISPOT
assays as described elsewhere (15). In brief, assays were performed
in 96-well MultiScreen filter plates (Merck Millipore, Watford,
Hertfordshire, UK) coated with 10µg/ml anti-IFN-γ (1-DIK,
Mabtech, Nacka Strand, Sweden). Phytohemagglutinin (5µg/ml,
PHA, final concentration 1µg/ml; Alere, Stockport, Cheshire,
UK) was used as a positive control. Plates were incubated for
16 h at 37°C and 5% CO2. Spot enumeration was performed
with an AID ELISPOT reader system (Autoimmun Diagnos-
tika GmbH, Ebinger Strasse, Straßberg, Germany). To quantify
antigen-specific responses, mean spots of the control wells were
subtracted from the positive wells, and the results are expressed
as SFU/106 PBMCs. Responses were considered positive if results
were at least three times the mean of the quadruplicate negative
control wells and >25 SFU/106 PBMCs. If negative control wells
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had >30 SFU/106 PBMCs or positive control wells (PHA stim-
ulation) were negative, the results were excluded from further
analysis.
Depletion of CD8+ T Cells
CD8+ T and CD4+ T cells were depleted with M-450 Dyn-
abeads (Invitrogen, Dynal, Oslo, Norway) according to man-
ufacturers’ instructions. This method has been validated and
widely used (15). Briefly, PBMCs from the same patient were
divided and incubated with anti-CD8 or anti-CD4 mAbs con-
jugated to ferrous beads in 0.1% FCS PBS medium at 4°C for
30min. The CD8+ and CD4+ T cells were removed using a
magnet stand (Invitrogen, Dynal). The efficiency of depletion was
assessed using a CyAn™ ADP flow cytometer (Dako, Ely, UK)
and FlowJo software (Tree Star Inc., Ashland, OR, USA). The
frequency of CD8+ T cells and CD4+ T cells was <1% after
depletion.
Tetramer Staining and Multicolor Flow Cytometry
Cryopreserved PBMCs were thawed as described above. A total of
1 106 live PBMCs were labeled with tetramer-PE:HLA-A*0201
complexed with M158–66 peptide GILGFVFTL, produced in-
house using standard methods (20), and incubated for 15min
at 37°C. Cells were then incubated with CD8-PerCP and CD4-
Pacific Blue (eBiosciences, Hatfield, UK), as well as a panel of
antibodies for cell activation and differentiation markers: CD28-
FITC, HLA-DR-APC, CD38-PE-Cy7, and CD27-APC-H7. Cells
allocated to the intracellular panels were permeabilized with
Perm/fix (BD, Oxford, UK) for 15min and washed twice with 1
perm/washing buffer (BD). Cells were then labeled with Perforin-
FITC (D48, Genprobe, Manchester, UK) or GranzymeA-FITC
and GranzymeB-PB (Biolegend, London, UK). Cells were subse-
quently washed twice with 1 perm/washing buffer and fixed in
BD cellfix (BD). All antibodies were from Becton Dickinson (BD,
Oxford, UK) unless otherwise stated. Cell events were acquired
on a nine-color CyAn Cytometer (Dako, Ely, UK), and data
files were analyzed using FlowJo software. Data were analyzed
using a forward side scatter gate followed by CD8 gating, then
tetramer gating within the CD8+ population. These cells were
then analyzed for percentage expression of a particular marker
using unstained and CD8+tet  populations to determine where
to place the gates. Single-color samples were run for compensa-
tion, and fluorescence minus one (FMO) control samples were
also applied to determine positive and negative populations, as
well as channel spillover.
T Cell Clones and EBV-Transformed B Cell Line
Cytotoxic T cell (CTL) clones specific for peptide H1 HA-56
were generated by limiting dilution from the PBMCs of study
subject ID24 and maintained as described by Dong et al. (21). An
autologous EBV-transformed B cell line was also generated from
this subject.
Intracellular Staining and Flow Cytometry
The following directly conjugated monoclonal antibodies
were obtained from BD Biosciences (BD, Oxford, UK): IFN-γ
(FITC), TNF-α (APC), CD107a (PE), CD3 (APC-H7), and CD8
FIGURE 1 | Flow diagram of the clinical trial study design.
(PE-Cy7). Antigen-specific CD8+ T cell clones were stimulated
with peptide-pulsed autologous B cells in the presence of anti-
CD107a for 1 h and incubated with 0.7µg/ml monensin (BD
Biosciences) and 10µg/ml Brefeldin A (BD Biosciences) for an
additional 5 h at 37°C. Negative controls included un-stimulated
cells. CD8+ T cell populations producing cytokines were fixed
and stained as described above and detected by flow cytometry.
Statistical Analysis
All statistical analyses were performed using Prism 6 (GraphPad
Software). p-values were calculated using the Wilcoxon matched-
pairs signed rank test or the Mann–Whitney test. p< 0.05 was
regarded as statistically significant.
Results
Study Subjects and Specimens
As described by Karron et al. (4), 21 healthy volunteers were
enrolled in this phase I clinical trial and received the H5N1 VN
2004 ca vaccine intranasally.With the exception of 2 study subjects
(ID31 and ID41), the remaining 19 study subjects received a
second dose of vaccine approximately 50 days later. As shown in
Figure 1, blood sampleswere taken from each study subject at four
time points (TP): pre-vaccination (first TP), 7 days after the first
dose (second TP), 1 day prior to the second dose (third TP), and
7 days after the second dose (fourth TP). Stored frozen PBMCs
were used for this study. Infection with vaccine virus occurred in
12 study subjects.
H5N1 pLAIV Vaccine Boosts Influenza-Specific
T Cell Responses
Significantly elevated T cell responses were observed to H5 HA
(p= 0.0068, Figure 2A) after first and second dose of vaccine;
elevated T cell responses toM andNP proteins were also observed
(Figure 2B, p= 0.036) (Figure 2B). We found that 12 of 21 study
subjects showed elevated T cell responses to the highly conserved
M and NP proteins after the first and/or second dose of pLAIV,
regardless of whether they had confirmed vaccine virus infection
(Figure 2C). These responses did not correlate with the anti-
body responses following ISIV boost administered in a follow-up
study (18).
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FIGURE 2 | Elevated T cell responses after each vaccination. T cell
responses at all four time points (TP) were screened by ex vivo IFN-γ ELISPOT
using overlapping peptides fromH1 HA, H3 HA, H5 HA, and H5N1 VN 2004
Matrix proteins (M1 and M2) and Nucleoprotein. n= 2 replicates.
(A) Comparison of T cell responses targeting H5 HA peptides pre- and post-
first and second vaccination (n= 21). (B) Comparison of T cell responses
targeting internal proteins M (n= 20) and NP (n= 19) pre- and post- first and
second vaccination. p-values were calculated using the Wilcoxon
matched-pairs signed rank test. (C) Study subjects who showed >2-fold
elevated T cell responses to M and NP peptides after vaccination.
The H5N1 pLAIV is able to Stimulate
Cross-Reactive T Cell Responses with an
Effector Phenotype, Specific to Internal Viral
Proteins
Wenext evaluated the phenotype of antigen-specific CD8+ T cells
by staining PBMCs with an MHC class I tetramer specific to an
HLA-A0201-restricted M1 protein (58–66) epitope and a panel
of antibodies specific for cell activation and cytotoxicity markers.
Figure 3A displays the gating strategy used in flow cytometry. T
cells from two study subjects (ID36 and ID42) who were infected
with the vaccine virus were positively stained with this tetramer.
Figure 3B clearly demonstrates that the proportion of CD8+
tetramer+ T cells increased after vaccination. In study subject
ID36, theCD8+ tetramer+ T cells expanded from0.038 to 0.067%
after the first dose of vaccine. Although the size of the antigen-
specific T cell population shrank slightly thereafter, from 0.067%
7 days after the first dose of vaccine to 0.057% 7 days following
the second dose of vaccine, it was still greater than the baseline
level. In study subject ID42, the CD8+ tetramer+ T cells were
boosted after each dose of vaccine, with an approximately 0.05%
increase post-vaccination. The number of antigen-specific T cells
increased, and there was an enhancement in expression levels of
cell activation and cytotoxicity molecules, such as CD38, HLA-
DR, and perforin, on the T cells (Figure 3C), indicating that
the H5N1 pLAIV could boost CD8+ T cells specific to internal
viral proteins with effector functions. Moreover, we also observed
stronger systematic activation of CD8+ T cells from study subjects
who were infected with the vaccine virus. As shown in Figure 3D,
the expression level of CD38 on the surface of CD8+ T cells was
higher after each dose of vaccine compared to pre-vaccination
levels.
Elevated HA-Specific T Cell Responses to
Seasonal Influenza Viruses with Low
Cross-Reactivity to H5N1 HA Peptides
Wealso observed elevated T cell-specific responses toHAproteins
of seasonal influenza viruses (H1 and H3) in 6 out of 21 subjects
following receipt of the H5 pLAIV vaccine (Figure 4A). The
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FIGURE 3 | HLA-A*0201 M158–66-specific T cells were boosted and
showed better effector function after each vaccine dose. (A) Gating
strategy. Gating of CD8+ tetramer+ cells, CD8+ CD38+ cells, CD8+
perforin+ cells, and CD8+ HLA-DR+ cells. The gating of CD38+,
Perforin+, and the HLA-DR+ population on antigen-specific T cells is same
as the gating on CD8+ T cells. The percentage of tetramer+ cells shown is
within CD8+ T cells. (B) Frequency of HLA-A*0201 M158–66 tetramer
positive cells before and after each vaccine dose. (C) Expression of
activation markers (CD38 and HLA-DR) and cytolytic marker (Perforin D48)
on HLA-A*0201 M158–66 tetramer positive cells before and after each
vaccine dose. Lines represent the percentage of tetramer positive cells with
the noted markers. (D) Comparison of CD38 expression on CD8+ T cells
before and after each vaccine dose in the vaccine virus-infected group (first
vaccination: n= 13; second vaccination: n= 11). p-Values were calculated
using the Wilcoxon matched-pairs signed rank test. For the scatter dot plots,
the line represents the median value.
enhanced responses to seasonal influenza virus HAs, particularly
H1 HA, were higher than the responses to the H5 HA pro-
tein (Figure 4B), indicating that the H5N1 pLAIV preferentially
boosted T cell responses to seasonal influenza HA proteins rather
than H5N1 HA in some individuals.
As illustrated in Figure 5A, both study subjects ID23 and ID24
displayed responses to peptide HA1-56 from the H1 HA protein,
and the responses were mainly elicited by CD8+ T cells. However,
our ex vivoELISPOTdata showed that theT cells did not recognize
the corresponding peptide from the H5 HA, known as HA5-
59 (Figure 5B). Subsequently, we generated CD8+ T cell clones
specific to the H1 HA1-56 peptide from study subject ID24 and
tested their cross-reactivity to the H5 HA5-59 peptide. As shown
in Figures 5C,D and Figure S1 in Supplementary Material, all
three T cell clones were capable of degranulation and producing
IFN-γ and TNF-α when stimulated by peptide HA1-56. However,
they did not show any responses to peptideHA5-59, even at a high
peptide concentration. These data suggest that T cell responses to
seasonal influenza HA proteins had low-level cross-reactivity to
the H5 HA, an example of original antigenic sin (OAS) for T cells.
High Pre-Existing Cross-Reactive Responses to
Internal Influenza Virus Proteins do not Restrict
Infectivity of the Vaccine Virus
On screening for T cell responses to internal influenza virus
proteins, we observed strong cross-reactive responses to internal
proteins of the H5N1 virus, especially M and NP, in some infected
study subjects prior to immunization. For example, as illustrated
in Figure 6A, study subjects ID27 and ID32 who were infected
with the H5N1 pLAIV vaccine, showed strong T cell responses to
theM protein before vaccination, with a level of IFN-γ production
>600 SFU/106 PBMCs. Among the study subjects infected with
the pLAIV, pre-existing T cell responses targeting the NP protein
were also detected in ID27, ID32, and ID34, with a magnitude
>250 SFU/106 PBMCs. There was no significant difference in
the pre-existing T cell responses targeting internal viral proteins
M and NP between the pLAIV-infected and un-infected groups
(Figures 6B,C, and data not shown). These data indicate that
high pre-existing cross-reactive responses to internal influenza
viral proteins are unlikely to have played a role in restricting the
infectivity of the vaccine virus.
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FIGURE 4 | T cell responses to seasonal influenza HA peptides were
elevated after the first and second dose of the pLAIV. (A) T cell responses
to H1 HA, H3 HA, and H5 HA peptides at all four time-points in six study
subjects. n= 2 replicates; Arrows represent documented vaccine virus infection.
(B) Comparison of T cell responses targeting H5 HA, H1 HA, and H3 HA pre-
and post- first and second vaccination, n= 6. p-Values were calculated using
the Wilcoxon matched-pairs signed rank test. For the scatter dot plots, the line
represents the median value.
Discussion
Vaccination with the H5N1 pLAIV stimulated modest influenza-
specific T cell responses in most vaccine recipients. The responses
were in both CD4+ and CD8+ T cells and the T cells showed
evidence of cytolytic function. There was no relationship between
the T cell responses and other evidence that of pLAIV vaccine
infection, either by PCR-detected shedding or a fourfold rise
antibody titer. Although the H5N1 pLAIV was highly restricted
in replication and was poorly immunogenic in the phase I clin-
ical trial, we recently showed that the H5N1 pLAIV induced
long-term immune memory (18). We detected a high titer, rapid
antibody response in most of the study subjects following the
administration of a single dose of an H5N1 inactivated subunit
influenza vaccine (ISIV) almost 5 years after the initial H5N1
pLAIV (18). Interestingly, pLAIV priming of these antibody
responses occurred even in the absence of significant vaccine
virus shedding and immunogenicity measured by traditional end
points in the initial phase I clinical trials of the H5N1 pLAIV
(18). In the current study, indications of antigen exposure by
significantly elevated T cell responses were observed after the first
and/or second dose of pLAIV in most volunteers; these responses
did not correlate either positively or negatively with the antibody
responses following ISIV boost. In a separate study in Vietnam,
we have detected H5N1-specific T cell responses in a village
cohort with H5N1 virus exposure, regardless of the detection
of antibodies (22). Thus, it is likely that exposure to infectious
influenza virus can sometimes stimulate CD8+ T cell responses
without inducing antibody responses or infecting sufficient cells
in the respiratory tract to be detectable by PCR or virus culture.
Detection of influenza virus-specific T cell responses may serve
as an additional marker for subclinical H5N1 virus infection in
humans.
T cell immune responses were detected targeting internal viral
proteins, which are highly conserved between different influenza
virus strains. These highly cross-reactive T cells are likely to
confer broader or potentially “universal” protection against a
wide range of influenza viruses (19). T cell responses, especially
cross-reactive T cell responses, correlate with protection in several
studies, including our own (14, 15). Although very low antibody
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FIGURE 5 | T cell responses to seasonal influenza HA proteins
showed a low level of cross-reactivity to H5 HA. (A) T cell responses
to peptide pools, single peptide, and responses to single peptide elicited
by CD4+ T cells from study subjects ID23 at time point 2 and ID24 at time
point 4. n=3 replicates. (B) Cross-recognition of peptides HA1-56 and
HA5-59 by T cells from study subject ID24 at all four time points. n= 3
replicates. Amino acids differing between HA1-56 and HA5-59 are shown
in gray italics. (C,D) Cross-recognition of peptides HA1-56 and HA5-59 by
T cell clones generated from study subject ID24. The cross-reactivity of T
cell clones was assessed by IFN-γ ELISPOT using titrated peptides
(C), degranulation (CD107a expression), and intracellular TNFα and IFN-γ
production (D).
responses were detected in pLAIV study subjects (9), our results
showed elevated T cell responses in >60% of study subjects in
response to at least one influenza virus internal protein (mostly to
M and NP protein,>2-fold increase) after the first and/or second
dose of vaccine. However, some increased responses were seen
50 days after the first vaccination but not at 7 days, suggesting that
further optimization of the timing of the T cell assays after LAIV
administration might be needed. Taken together, the advantages
and potential of evaluating T cell responses against internal viral
proteins, especially M and NP, along with neutralization and HAI
antibody responses might be considered for future evaluation of
vaccine immunogenicity.
Elevated HA-specific T cell responses to seasonal H1 and H3
influenza viruses, with low cross-reactivity to H5N1 HA pep-
tides were detected in study subjects after the first or second
dose of H5N1 pLAIV, suggesting an “original antigenic sin”
phenomenon. Original antigenic sin in T cells in humans was first
described for dengue viruses by Mongkolsapaya et al. (23) and
implies that the response to a secondary infection by a dengue
virus is dominated by the proliferation of cross-reacting memory
T cells induced by primary infection with a different viral strain,
which is of lower affinity for the secondary viral antigen. However,
whether this will be to the benefit or the detriment of the host
remains unanswered.
Finally, the presence of high level pre-immunization T cell
responses in three volunteers did not prevent boosting of T cell
responses. Therefore, this does not appear to be the reasonwhy the
pLAIV did not infect all the study subjects. However, as discussed
above, the vaccine boosted T cell responses in the absence of
detectable virus shedding or a rise in antibody titer. It is likely
therefore that low-level infection by the attenuated pLAIV rather
variably stimulates both T and B cell responses.
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FIGURE 6 | T cell responses targeting H5N1 internal viral proteins.
(A) Examples of the study subjects from the vaccine virus-infected group
(ID27, ID32, and ID34) who showed high pre-existing cross-reactive T cell
responses. n= 2 replicates. Arrows represent documented vaccine virus
infection. (B) Comparison of pre-existing cross-reactive T cell responses
targeting the viral M proteins between the vaccine virus-infected (n= 13) and
un-infected (n= 7) study subjects. (C) Comparison of pre-existing
cross-reactive T cell responses targeting NP protein between the vaccine
virus-infected (n= 12) and un-infected (n= 7) study subjects. Study subject
ID29 was excluded because of limited cell numbers. p-values were
calculated using the Mann–Whitney test. For the scatter dot plots (B,C), the
line represents the median value.
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